| 产品编号 | bs-0429R |
| 英文名称 | WNK4 |
| 中文名称 | WNK4抗体 |
| 别 名 | PHA 2B; PHA2B; PRKWNK 4; PRKWNK4; Protein kinase lysine deficient 4; Protein kinase with no lysine 4; Serine/threonine protein kinase WNK4; WNK lysine deficient protein kinase 4; WNK4_HUMAN. |
| 研究领域 | 心血管 免疫学 激酶和磷酸酶 通道蛋白 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Mouse (predicted: Human,Rat) |
| 产品应用 | WB=1:500-2000, ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 135kDa |
| 细胞定位 | 细胞浆 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human WNK4: 351-450/1243 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
Regulates the activity of the thiazide-sensitive Na-Cl cotransporter, SLC12A3, by phosphorylation which appears to prevent membrane trafficking of SLC12A3. Also inhibits the renal K(+)channel, KCNJ1, via a kinase-independent mechanism by which it induces clearance of the protein from the cell surface by clathrin-dependent endocytosis. WNK4 appears to act as a molecular switch that can vary the balance between NaCl reabsorption and K(+)secretion to maintain integrated homeostasis. Function: Serine/threonine kinase which plays an important role in the regulation of electrolyte homeostasis, cell signaling, survival and proliferation. Acts as an activator and inhibitor of sodium-coupled chloride cotransporters and potassium-coupled chloride cotransporters respectively. Activates SCNN1A, SCNN1B, SCNN1D, SGK1, TRPV5 and TRPV6. Regulates the activity of the thiazide-sensitive Na-Cl cotransporter, SLC12A3, by phosphorylation which appears to prevent membrane trafficking of SLC12A3. Also inhibits the renal K(+) channel, KCNJ1, via a kinase-independent mechanism by which it induces clearance of the protein from the cell surface by clathrin-dependent endocytosis. WNK4 appears to act as a molecular switch that can vary the balance between NaCl reabsorption and K(+) secretion to maintain integrated homeostasis. Phosphorylates NEDD4L. Subunit: Interacts with the C-terminal region of KCNJ1 (By similarity). Interacts with WNK1 and WNK3 (By similarity). Subcellular Location: Cell junction, tight junction (By similarity). Note=Present exclusively in intercellular junctions in the distal convoluted tubule and in both the cytoplasm and intercellular junctions in the cortical collecting duct. WNK4 is part of the tight junction complex (By similarity). Tissue Specificity: Expressed in kidney, colon and skin. Post-translational modifications: Phosphorylated by WNK1 and WNK3. DISEASE: Pseudohypoaldosteronism 2B (PHA2B) [MIM:614491]: An autosomal dominant disorder characterized by hypertension, hyperkalemia, hyperchloremia, mild hyperchloremic metabolic acidosis, and correction of physiologic abnormalities by thiazide diuretics. Note=The disease is caused by mutations affecting the gene represented in this entry. Similarity: Belongs to the protein kinase superfamily. Ser/Thr protein kinase family. WNK subfamily. Contains 1 protein kinase domain. SWISS: Q96J92 Gene ID: 65266 Database links: Entrez Gene: 65266 Human Omim: 601844 Human SwissProt: Q96J92 Human Unigene: 105448 Human WNK4蛋白是一种新的丝氨酸/苏氨酸激酶家族成员的基因，在远端肾小管表达（肾小管是肾脏的基本结构，在维持人体的水电解质平衡方面有着重要的作用）而且，这一发现还有助于人们更好的了解肾脏的生理作用。 WNK4基因的发现是非常有意义的，WNK4的突变可能会引起高血压病的发生,为人们研究血压变化的发生机理提供了一个线索。 |
| 产品图片 |
Sample: Eye(Mouse) Lysate at 30 ug
Primary: Anti- WNK4 (bs-0429R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 135 kD Observed band size: 135 kD |
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
